Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 5Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Desmoid Tumors 1Craniopharyngioma 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Anal Cancer Metastatic 1Adenomatous Polyposis Coli 1

Interventions

nirogacestat 3Nivolumab 2trifluridine tipiracil drug combination 1Specimen Handling 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ipilimumab 1Fluorouracil 1Electrochemotherapy 1Doxorubicin 1Cryosurgery 1CTLA-4 Antigen 1Bleomycin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Desmoid Tumors × trifluridine tipiracil drug combination × 30 days × Clear all
NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡